<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549416</url>
  </required_header>
  <id_info>
    <org_study_id>18/239</org_study_id>
    <nct_id>NCT03549416</nct_id>
  </id_info>
  <brief_title>BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients With Atopic Dermatitis</brief_title>
  <acronym>BioDay</acronym>
  <official_title>BioDay Registry: Prospective, Observational Data Collection Regarding the Use of New Systemic Treatment Options in Patients With Atopic Diseases in Daily Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Ziekenhuis Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BioDay Registry aims to address the need for daily practice data regarding the
      effectiveness and safety of new systemic treatment options in patients with AD and effect on
      other atopic comorbidities in a multicenter setting. The registry already consists of several
      additional modules concerning atopic comorbidities, like food allergy and asthma, and a
      module for conjunctivitis during dupilumab treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Assessment of effectiveness</measure>
    <time_frame>Change from baseline to previous specified timepoints (16 weeks, 1 year, 2 year etc.)</time_frame>
    <description>To assess the effectiveness of new treatments in adult and pediatric patients with AD using physician measured clinical eczema scores as well as patient-reported outcome measures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug survival</measure>
    <time_frame>Drug survival analysis, which is the length of time a patient continues to take a particular drug, will be performed every year, with cumulative results over the years.</time_frame>
    <description>To study drug survival and identify factors that affect drug survival.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Side effects</measure>
    <time_frame>Change from baseline to previous specified timepoints (16 weeks, 1 year, 2 year etc.)</time_frame>
    <description>To register objective and subjective side effects and to identify potential risk factors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of population</measure>
    <time_frame>Yearly from baseline up to 5 years</time_frame>
    <description>To characterize patient populations treated with new AD treatments in daily practice.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of side effects</measure>
    <time_frame>Yearly from baseline up to 5 years</time_frame>
    <description>To collect data from daily practice regarding side effects (incidence, severity, risk factors, treatment options, etc.).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory monitoring</measure>
    <time_frame>Yearly from baseline up to 5 years</time_frame>
    <description>To study the usefulness of laboratory monitoring during treatment in daily practice, with emphasis on subpopulations (e.g. elderly patients, patients with pre-existing liver and/or renal disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term safety</measure>
    <time_frame>Yearly from baseline up to 5 years</time_frame>
    <description>To study the long-term safety risks including malignancies, pregnancy/paternity-related conditions, infections, and autoimmune diseases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidities</measure>
    <time_frame>Yearly from baseline up to 5 years</time_frame>
    <description>To prospectively collect data from daily practice regarding the effect of new treatment options for AD on comorbidities (for example atopic diseases like asthma, food allergy and rhinoconjunctivitis can improve from these new drugs as many target the Th2 axis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose tapering</measure>
    <time_frame>Yearly from baseline up to 5 years</time_frame>
    <description>To assess whether dose reduction of biologics can be achieved in patients with low AD activity.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Atopic Dermatitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All adult and paediatric patients treated with new systemic treatments for AD will be asked
        for participation in the BioDay Registry
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult and paediatric patients treated with new systemic treatments for AD will be
             asked for participation in the BioDay Registry

        Exclusion Criteria:

          -  Patients are not eligible for enrolment in case of presumed inability to answer
             questionnaires or not willing to answer questionnaires and will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ischa Kummeling, PhD</last_name>
    <phone>+31887550930</phone>
    <email>i.kummeling@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jorien van der Schaft, MD, PhD</last_name>
    <email>j.vanderschaft-5@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marijke Kamsteeg, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anneke van Lynden- van Nes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf ziekenhuis</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge Haeck</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haga ziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annemoon Tuyll van Serooskerken</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wouter Touwslager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Loiuse Schuttelaar, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bert Oosting</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht Univeristy Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula van Lumig</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjolein de Bruin-Weller, PhD</last_name>
      <phone>+31887550930</phone>
      <email>m.s.debruin-weller@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jorien van der Schaft, MD, PhD</last_name>
      <email>j.vanderschaft-5@umcutrecht.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annebeth Flinterman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Antonius ziekenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ron Tupker</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Dr M.S. de Bruin-Weller</investigator_full_name>
    <investigator_title>M.S. de Bruin-Weller, dermatologist, PhD</investigator_title>
  </responsible_party>
  <keyword>Atopic dermatitis</keyword>
  <keyword>Dupilumab</keyword>
  <keyword>Dupixent</keyword>
  <keyword>BioDay</keyword>
  <keyword>Daily practice</keyword>
  <keyword>Real world</keyword>
  <keyword>Atopic Diseases Registry</keyword>
  <keyword>Registry</keyword>
  <keyword>Multi center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

